Development of Tumor Organoids from Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Launched by CENTRE FRANCOIS BACLESSE · Sep 23, 2024
Trial Information
Current as of July 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to develop tumor organoids, which are tiny lab-grown versions of tumors, from patients with a type of cancer called undifferentiated primary carcinoma (UPC). The main goal is to use these organoids to help doctors predict how well different treatments might work for individual patients. This could lead to more personalized and effective treatment options for people with UPC.
To be eligible for this trial, participants must be adults diagnosed with undifferentiated primary carcinoma and have a recommendation for their first treatment. They should also have a life expectancy of more than three months and must be able to give their consent to participate. Unfortunately, those who are pregnant or breastfeeding, or who are under legal guardianship, cannot take part. If you join the trial, you will contribute to important research that may help improve treatment approaches for future patients with this type of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
- • Patient with indication for 1st-line treatment at the time of inclusion.
- • Patient with life expectancy greater than 3 months
- • Patient of legal age
- • Patient affiliated to a social security scheme
- • Signature of informed consent prior to any specific study procedure
- Exclusion Criteria:
- • Persons deprived of their liberty or under guardianship (including curatorship)
- • Pregnant or breast-feeding patient
About Centre Francois Baclesse
The Centre François Baclesse is a leading cancer research and treatment facility in France, dedicated to advancing oncology through innovative clinical trials and cutting-edge medical care. Renowned for its multidisciplinary approach, the center integrates comprehensive patient management with pioneering research initiatives, focusing on developing new therapies and improving existing treatments for various cancer types. With a commitment to enhancing patient outcomes, the Centre François Baclesse collaborates with national and international partners to contribute to the global body of knowledge in cancer treatment and research, making it a pivotal player in the fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Caen, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported